News Release Details
Opiant Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Data Supporting Potential of OPNT003, Nasal Nalmefene, for Treatment of Synthetic Opioid Overdose
“This pilot PK study demonstrates that, in the presence of Intravail®, the absorption of nasal nalmefene is rapid enough to be administered in an overdose rescue situation, when the first minutes are critical,” said
“The opioid epidemic is now a crisis of high-potency synthetic opioids, in particular fentanyl, and we must fight fire with fire to save lives,” said
About Synthetic Opioids
Synthetic opioids, such as fentanyl, are responsible for more overdose deaths than either heroin or prescription opioids, with over 28,000 fatalities linked to synthetic opioids in 2017. Synthetic opioids are more potent than heroin (e.g., fentanyl is 50 times more potent than heroin), and especially dangerous because of a rapid onset of action and long half-life. These properties of fentanyl and related synthetic opioids may require continuous monitoring of overdose victims and repeated dosing with short-acting reversal agents like naloxone to initially resuscitate a patient and prevent relapse. A long-acting opioid overdose reversal drug may reduce this burden.
OPNT003, nasal nalmefene, is in development as a potent, rapid-onset, long-acting opioid antagonist for the treatment of opioid overdose. OPNT003 is designed as a rescue medication that could be especially useful in treating overdose by high-potency synthetic opioids, such as fentanyl. OPNT003 is also being considered as an antidote in a civilian mass casualty event. The development of OPNT003 is supported by grants from the NIH and the
Intravail® is a registered trademark of
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, and among other things, our ability to maintain cash balances and successfully commercialize or partner our product candidates currently under development. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. Additional factors that could materially affect actual results can be found in our Form 10-K for the year ended
|For Media Inquiries:||For Investor Inquiries:|
|Peter Duckler, W2O||Dan Ferry, LifeSci Advisors, LLC|
|(773) 343-3069||(617) 535-7746|
Source: Opiant Pharmaceuticals, Inc.